On Friday, April 10, 2026 at 1:00 p.m. ET, join ALS Canada for our next ALS Clinical Trials Unboxed webinar to learn more about ongoing ALS clinical trials.
Coya Therapeutics will present an overview of the ALSTARS clinical trial, an ongoing study evaluating COYA 302 as a potential treatment for individuals living with amyotrophic lateral sclerosis (ALS).
During this session, Dr. Tyrell J. Simkins, DO, PhD, Senior Director of Clinical Development at Coya Therapeutics, will discuss the scientific rationale behind COYA 302 and the design of the ALSTARS trial. The presentation will review the mechanism of action of COYA 302, key elements of the study design, eligibility considerations, participating sites including Canadian centers, and the primary goals and outcome measures of the trial.
Dr. Simkins will be joined by Daniel Barvin, Vice President of Operations & Patient Advocacy at Coya Therapeutics, who will provide additional perspective on patient engagement, trial access, and Coya’s commitment to working collaboratively with the ALS community. Mr. Barvin will also help address questions related to study participation and ongoing advocacy efforts supporting individuals and families affected by ALS.
Please note that ALS Canada does not provide medical advice or make referrals related to drug therapies or alternative therapies. These questions should be discussed directly with a medical professional – ideally an ALS neurologist, who would be qualified to interpret clinical information for individual situations.
Please visit our list of ALS clinics to help you to connect with a clinic in your area.
